New Patents Awarded To BioLife Solutions

Pixabay License | Source: Orlando , no changes made.
Advertisement img

BioLife Solutions, Inc., a leading developer and supplier of best-in-class bioproduction tools for cell and gene therapies, has announced the awarding of three new patents for inventions related to cryopreservation, thawing and cold chain transport technologies.

BioLife Solutions, founded in 1987, headquartered in the Greater Seattle Area, west coast USA, is the leading developer, manufacturer and supplier of proprietary biopreservation media for cells and tissues. HypoThermosol® hypothermic storage and CryoStor® cryopreservation freeze media are highly valuable in the regenerative medicine, biobanking and drug discovery markets.

The recently acquired ThawStar® family of automated cell thawing products and evo cold chain management system reduce therapeutic and economic risk for cell and gene therapy developers by reducing the potential of administering a non-viable dose.

Featured Partners

According to the company the new patents awarded to BioLife include:

  • European Patent: Apparatuses and Compositions for Cryopreservation of Cellular Monolayers
  • United States Patent: Systems, Devices and Methods for Automated Sample Thawing
  • United States Patent: Insulated Storage and Transport System

These patents include claims related to facilitating bulk freezing of adherent cells in multi-well plates for use in high-throughput drug screening processes, core technologies used in the ThawSTAR® automated thawing products, which BioLife obtained in the acquisition of Astero Bio in April 2019, and core technologies used in the evo® cloud-connected precision thermal shipping containers, which BioLife obtained in the acquisition of SAVSU Technologies in August 2019.

“We have a remarkably strong team of inventors who are experts in the fields of cryopreservation, storage and transport, and thawing of biologic material; specifically, for cell and gene therapies targeting the leading causes of disabilities and death. Our scientific team has several additional pending patents covering novel features of our best-in-class portfolio of bioproduction tools. We look forward to providing a continuous stream of innovative solutions to the high growth cell and gene therapy market.” – Mike Rice, CEO, BioLife Solutions